Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Myeloproliferative Disorders 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

Imatinib Mesylate 60Cyclophosphamide 57fludarabine phosphate 51fludarabine 43Whole-Body Irradiation 41Mycophenolic Acid 41Tacrolimus 33nilotinib 31Dasatinib 31Busulfan 29Peripheral Blood Stem Cell Transplantation 23Cyclosporine 22Melphalan 21Thiotepa 20Granulocyte Colony-Stimulating Factor 19Filgrastim 18thymoglobulin 17Cytarabine 17Antilymphocyte Serum 15Stem Cell Transplantation 14sargramostim 13Methotrexate 13ponatinib 12asciminib 10Cyclosporins 10Cord Blood Stem Cell Transplantation 10bosutinib 9Rituximab 9Interferon-alpha 9Clofarabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × olverembatinib × Clear all
NCT06817720 2026-05-20

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04126681 2025-03-03

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Ascentage Pharma Group Inc.

Phase 2 Completed
144 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡